专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090068689A1 Molecular phenotyping of severe asthma 有权
标题翻译：严重哮喘的分子表型
公开(公告)号：US20090068689A1
公开(公告)日：2009-03-12
申请号：US12220263
申请日：2008-07-22
申请人： Allan R. Brasier , William J. Calhoun , Gary D. Boetticher
发明人： Allan R. Brasier , William J. Calhoun , Gary D. Boetticher
IPC分类号： G01N33/68
CPC分类号： G01N33/6863 , G01N2333/522 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/5443 , G01N2333/55 , G01N2800/122
摘要： The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.
摘要翻译：本发明公开了一种基于细胞因子表达模式将个体分类为具有气道高反应性和哮喘患者的方法。预期这种方法将能够快速鉴定需要对哮喘进行强化治疗的个体，从而降低发病率并改善受影响者的生活质量。

2. 发明授权

US11117865B2 Inhibitors of bromodomain-containing protein 4 (BRD4) 有权
公开(公告)号：US11117865B2
公开(公告)日：2021-09-14
申请号：US16442526
申请日：2019-06-16
申请人： Jia Zhou , Allan R. Brasier , Bing Tian , Zhiqing Liu , Haiying Chen , Erik Rytting
发明人： Jia Zhou , Allan R. Brasier , Bing Tian , Zhiqing Liu , Haiying Chen , Erik Rytting
IPC分类号： A61K9/14 , A61P29/00 , C07D311/00 , C07D215/38 , C07D207/48 , C07D241/04 , C07D311/30 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/04 , C07D413/06 , C07D413/14 , C07D471/04
摘要： Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

3. 发明授权

US5804445A High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor 失效
标题翻译：核因子白介素-6的高亲和力突变体及其使用方法
公开(公告)号：US5804445A
公开(公告)日：1998-09-08
申请号：US585197
申请日：1996-01-11
申请人： Allan R. Brasier
发明人： Allan R. Brasier
IPC分类号： A61K38/00 , C07K14/47 , C07K14/435 , C12N1/20 , C12N15/85
CPC分类号： C07K14/4705 , A61K38/00
摘要： The present invention relates to inhibitors of the sequence specific transcription factor nuclear factor IL-6 (NF-IL6) and methods of use therefor. In particular, substitution mutants in the N-terminus of the NF-IL6 tryptic core domain are disclosed that have a higher binding affinity for the DNA binding site than does the wild-type sequence.
摘要翻译：本发明涉及序列特异性转录因子核因子IL-6（NF-IL6）的抑制剂及其用途。特别地，公开了与野生型序列相比，对DNA结合位点具有更高的结合亲和力的NF-IL6胰蛋白酶核心结构域的N末端的取代突变体。

4. 发明申请

US20210063394A1 METHODS AND COMPOSITIONS FOR DIAGNOSIS OF RICKETTSIA INFECTION 有权
公开(公告)号：US20210063394A1
公开(公告)日：2021-03-04
申请号：US17004309
申请日：2020-08-27
申请人： Allan R. BRASIER , Yingxin ZHAO , David H. WALKER , Rong FANG
发明人： Allan R. BRASIER , Yingxin ZHAO , David H. WALKER , Rong FANG
IPC分类号： G01N33/569 , G01N33/563
摘要： Certain embodiments are directed to detection methods and methods of identifying detection targets for sensitive and specific laboratory tests to diagnose and monitor rickettsial infections during the earliest stages of the disease and to assess the degree of illness.

5. 发明授权

US08053199B2 Molecular phenotyping of severe asthma 有权
标题翻译：严重哮喘的分子表型
公开(公告)号：US08053199B2
公开(公告)日：2011-11-08
申请号：US12220263
申请日：2008-07-22
申请人： Allan R. Brasier , William J. Calhoun , Gary D. Boetticher
发明人： Allan R. Brasier , William J. Calhoun , Gary D. Boetticher
IPC分类号： G01N33/53
CPC分类号： G01N33/6863 , G01N2333/522 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/5443 , G01N2333/55 , G01N2800/122
摘要： The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.
摘要翻译：本发明公开了一种基于细胞因子表达模式将个体分类为具有气道高反应性和哮喘患者的方法。预期这种方法将能够快速鉴定需要对哮喘进行强化治疗的个体，从而降低发病率并改善受影响者的生活质量。

6. 发明授权

US07521534B1 IKK gamma gene products and methods for making and using same 有权
标题翻译： IKKγ基因产物及其制造和使用方法
公开(公告)号：US07521534B1
公开(公告)日：2009-04-21
申请号：US10793339
申请日：2004-03-03
申请人： Allan R. Brasier , Tao Hai , Thomas G. Wood , Yuanfen Wei
发明人： Allan R. Brasier , Tao Hai , Thomas G. Wood , Yuanfen Wei
IPC分类号： C07K1/00
CPC分类号： C07K14/4702
摘要： Disclosed are isolated IKKγΔ; isolated nucleic acid molecules encoding IKKγΔ; expression vectors and cells which contain such nucleic acid molecules; oligonucleotides which are complementary to at least a portion of nucleic acid molecules encoding IKKγΔ but which are not complementary to any portion of nucleic acid molecules encoding wild type IKKγ; antibodies which are specific for IKKγΔ; DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKKγΔ; and DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKKγΔ but which do not hybridize with nucleic acid molecules encoding wild type IKKγ. Methods for using these materials to inhibit formation of IKKγΔ-containing IKK, to inhibit NF-κB activation, and to treat or prevent inflammation are also disclosed.
摘要翻译：披露的是孤立的IKKgammaDelta; 编码IKKgammaDelta的分离的核酸分子; 含有此类核酸分子的表达载体和细胞; 与编码IKKgammaDelta的核酸分子的至少一部分互补但与编码野生型IKKgamma的核酸分子的任何部分不互补的寡核苷酸; 对IKKgammaDelta特异的抗体; 任选具有标记或酶活性形式的DNA和RNA寡聚体，其能够与编码IKKgammaDelta的核酸分子选择性杂交; 以及任选具有标记或酶活性形式的DNA和RNA寡聚体，其能够与编码IKKgammaDelta但不与编码野生型IKKgamma的核酸分子杂交的核酸分子选择性杂交。还公开了使用这些材料抑制含有IKKgammaDelta的IKK的形成，抑制NF-κB活化以及治疗或预防炎症的方法。

7. 发明授权

US06699459B2 Methods of treating lung inflammation 失效
标题翻译：治疗肺部炎症的方法
公开(公告)号：US06699459B2
公开(公告)日：2004-03-02
申请号：US10087319
申请日：2002-03-01
申请人： Antonella Casola , Roberto Garofalo , Allan R. Brasier
发明人： Antonella Casola , Roberto Garofalo , Allan R. Brasier
IPC分类号： A61K912
CPC分类号： A61K31/085 , Y10S514/826
摘要： The present invention relates to a method of treating lung inflammation in a subject which includes administering butylated hydroxyanisol to the subject in an amount effective to treat lung inflammation. The invention also relates to methods of inhibiting interferon regulatory factor activation in a subject and in an alveolar cell. Another aspect of the invention relates to an assay.
摘要翻译：本发明涉及一种治疗受试者的肺部炎症的方法，其包括以有效治疗肺部炎症的量向受检者施用丁基化羟基苯甲醚。本发明还涉及抑制受试者和肺泡细胞中干扰素调节因子活化的方法。本发明的另一方面涉及一种测定。

8. 发明授权

US06423493B1 Combinatorial selection of oligonucleotide aptamers 有权
标题翻译：组合选择寡核苷酸适体
公开(公告)号：US06423493B1
公开(公告)日：2002-07-23
申请号：US09425798
申请日：1999-10-25
申请人： David G. Gorenstein , David J. King , Daniel A. Ventura , Allan R. Brasier
发明人： David G. Gorenstein , David J. King , Daniel A. Ventura , Allan R. Brasier
IPC分类号： C12Q168
CPC分类号： C12N15/115 , A61K38/00 , C07H21/00 , C12N15/1048 , C12N2310/313 , C12N2310/315 , C40B40/00
摘要： A random combinatorial selection method is disclosed for the construction of oligonucleotide aptamers in which nuclease resistance is conferred by the inclusion of modified nucleotides. The modified nucleotides are incorporated during PCR amplification to form achiral modified oligonucleotides. Thio-substituted aptamers are provided that bind tightly to the nuclear factor for human IL6 (NF-IL6).
摘要翻译：公开了随机组合选择方法，用于构建其中通过包含修饰的核苷酸赋予核酸酶抗性的寡核苷酸适体。在PCR扩增期间掺入修饰的核苷酸以形成非手性修饰的寡核苷酸。提供与人IL6（NF-IL6）的核因子紧密结合的硫替代的适体。

9. 发明授权

US09018367B2 Single stranded DNA aptamers binding NF-κB/RelA 有权
标题翻译：单链DNA适配体结合NF-和kgr; B / RelA
公开(公告)号：US09018367B2
公开(公告)日：2015-04-28
申请号：US13445558
申请日：2012-04-12
申请人： Steven G. Widen , Thomas G. Wood , Allan R. Brasier , Yingxin Zhao
发明人： Steven G. Widen , Thomas G. Wood , Allan R. Brasier , Yingxin Zhao
IPC分类号： C07H21/00 , A61K49/00 , A61K47/48 , A61K31/7088 , C12N15/115
CPC分类号： C12N15/115 , A61K31/7088 , A61K47/549 , A61K47/6455 , A61K49/0002 , C12N2310/16 , C12N2310/3517 , G01N33/5308 , G01N2333/47
摘要： DNA aptamers are high affinity ligands selected by genetic enrichment techniques to bind to specific protein targets. Because these represent chemically stable and reproducible molecules, they have application as affinity reagents and/or therapeutic drugs to affect the target protein's actions. NF-kB is an important mediator of the innate immune response and mediator of tissue inflammation. Although RNA and double stranded DNA aptamers have been identified to bind to the NF-kB family of proteins, the present invention represents the first identification of single stranded DNA aptamers that recognize NFkB RelA. The aptamers disclosed herein bind to several distinct regions of RelA and may be useful to antagonize the DNA binding of RelA as an inhibitor of cellular inflammation, visualize the location or amount of RelA in tissues from pathological conditions, or to quantitatively measure the activated state of RelA by affinity binding.
摘要翻译： DNA适体是通过遗传富集技术选择以结合特异性蛋白质靶标的高亲和力配体。因为它们代表化学上稳定和可重复的分子，所以它们作为亲和试剂和/或治疗药物的应用来影响靶蛋白的作用。 NF-kB是组织炎症的先天免疫反应和介质的重要介质。尽管RNA和双链DNA适体已被鉴定为与NF-kB蛋白家族结合，但本发明代表识别NFkB RelA的单链DNA适体的首次鉴定。本文公开的适体结合RelA的几个不同区域，并且可用于拮抗RelA作为细胞炎症抑制剂的DNA结合，可视化来自病理状况的组织中RelA的位置或数量，或定量测量 RelA通过亲和力绑定。

10. 发明申请

US20120263651A1 Single Stranded DNA Aptamers Binding NF-kB/RelA 有权
标题翻译：单链DNA适配子结合NF-kB / RelA
公开(公告)号：US20120263651A1
公开(公告)日：2012-10-18
申请号：US13445558
申请日：2012-04-12
申请人： Steven G. Widen , Thomas G. Wood , Allan R. Brasier , Yingxin Zhao
发明人： Steven G. Widen , Thomas G. Wood , Allan R. Brasier , Yingxin Zhao
IPC分类号： A61K31/7088 , G01N27/62 , C12N5/071 , G01N21/64 , G01N27/72 , A61K49/00 , A61P29/00 , A61P1/00 , A61P11/06 , A61P35/00 , A61K9/127 , G01N33/566 , C07H21/04 , B82Y15/00
CPC分类号： C12N15/115 , A61K31/7088 , A61K47/549 , A61K47/6455 , A61K49/0002 , C12N2310/16 , C12N2310/3517 , G01N33/5308 , G01N2333/47
摘要： DNA aptamers are high affinity ligands selected by genetic enrichment techniques to bind to specific protein targets. Because these represent chemically stable and reproducible molecules, they have application as affinity reagents and/or therapeutic drugs to affect the target protein's actions. NF-kB is an important mediator of the innate immune response and mediator of tissue inflammation. Although RNA and double stranded DNA aptamers have been identified to bind to the NF-kB family of proteins, the present invention represents the first identification of single stranded DNA aptamers that recognize NFkB RelA. The aptamers disclosed herein bind to several distinct regions of RelA and may be useful to antagonize the DNA binding of RelA as an inhibitor of cellular inflammation, visualize the location or amount of RelA in tissues from pathological conditions, or to quantitatively measure the activated state of RelA by affinity binding.
摘要翻译： DNA适体是通过遗传富集技术选择以结合特异性蛋白质靶标的高亲和力配体。因为它们代表化学上稳定和可重复的分子，所以它们作为亲和试剂和/或治疗药物的应用来影响靶蛋白的作用。 NF-kB是组织炎症的先天免疫反应和介质的重要介质。尽管RNA和双链DNA适体已被鉴定为与NF-kB蛋白家族结合，但本发明代表识别NFkB RelA的单链DNA适体的首次鉴定。本文公开的适体结合RelA的几个不同区域，并且可用于拮抗RelA作为细胞炎症抑制剂的DNA结合，可视化来自病理状况的组织中RelA的位置或数量，或定量测量 RelA通过亲和力绑定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式